论文部分内容阅读
目的:观察依普沙坦治疗冠心病合并高血压患者的疗效和安全性。方法:160例冠心病合并高血压患者随机均分为观察组和对照组。两组患者均给予阿司匹林、硝酸甘油、低分子肝素、他汀类药物等常规治疗,对照组患者在常规治疗的基础上给予氯沙坦钾片50 mg,口服,每日1次;观察组患者在常规治疗的基础上给予依普沙坦片600 mg,口服,每日1次。两组疗程均为6个月。观察两组患者的临床疗效,治疗前后坐位收缩压、坐位舒张压、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、尿素(UREA)、肌酐(Cr)、尿酸(UA)、总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、简易精神状态量表(MMSE)评分、日常生活能力量表(ADL)评分及不良反应发生情况。结果:两组患者总有效率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者坐位收缩压、坐位舒张压、MMSE评分、ADL评分均显著低于同组治疗前,且观察组坐位收缩压低于对照组,差异均有统计学意义(P<0.05);两组患者坐位舒张压、MMSE评分、ADL评分组间比较,差异均无统计学意义(P>0.05);两组患者治疗前后ALT、AST、UREA、Cr、UA、TC、TG、HDL-C、LDL-C比较,差异均无统计学意义(P>0.05)。两组患者治疗期间均未见明显不良反应发生。结论:依普沙坦可有效降低冠心病合并高血压患者坐位收缩压,改善认知功能,安全性较好。
Objective: To observe the efficacy and safety of eppastat in the treatment of patients with coronary heart disease complicated with hypertension. Methods: 160 cases of CHD with hypertension were randomly divided into observation group and control group. Patients in both groups were given routine treatment with aspirin, nitroglycerin, low molecular weight heparin, and statins. Patients in the control group were treated with losartan potassium 50 mg orally and once daily. Patients in the observation group were treated with On the basis of routine treatment, eprosartan 600 mg given orally once daily. Two courses of treatment are 6 months. The clinical efficacy, systolic blood pressure, sitting diastolic blood pressure, alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea (UREA), creatinine (Cr), uric acid (UA) TC, TG, HDL-C, LDL-C, MMSE score, daily living ability scale (ADL) score and the occurrence of adverse reactions. Results: There was no significant difference in the total effective rate between the two groups (P> 0.05). After treatment, the systolic blood pressure, sitting diastolic pressure, MMSE score and ADL score of the two groups were significantly lower than those of the same group before treatment, and the systolic pressure of the sitting group was lower than that of the control group (P <0.05). There were no significant differences in sitting diastolic pressure, MMSE score and ADL score between the two groups (P> 0.05). The levels of ALT, AST, UREA, Cr, UA, TC, TG, HDL-C , LDL-C, the difference was not statistically significant (P> 0.05). No significant adverse reactions occurred in both groups during treatment. Conclusion: Eprosartan can effectively reduce the sitting systolic pressure in patients with coronary heart disease complicated with hypertension and improve cognitive function, which is safe.